Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — Read more »
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
JERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, reports [...] Read more »
King Faisal Specialist Hospital and Research Centre gibt Start des innovativen klinischen Pharmakogenomik-Dienstes bekannt
RIAD, Saudi–Arabien, Oct. 25, 2023 (GLOBE NEWSWIRE) — The King Faisal Specialist Hospital and Research Centre (KFSH&RC) ist stolz darauf, den Start der ersten Phase seines klinischen [...] Read more »
King Faisal Specialist Hospital and Research Centre Lança Inovadora Farmacogenômica Clínica
RIADE, Arábia Saudita, Oct. 25, 2023 (GLOBE NEWSWIRE) — O King Faisal Specialist Hospital and Research Centre (KFSH&RC) tem o orgulho de anunciar o lanamento da fase inaugural do seu servio de farmacogenmica [...] Read more »
Le King Faisal Specialist Hospital & Research Center annonce le lancement d’un service de pharmacogénomique clinique innovant
RIYADH, Arabie saoudite, 25 oct. 2023 (GLOBE NEWSWIRE) — Le King Faisal Specialist Hospital and Research Centre ( KFSH&RC ) est fier d'annoncer le lancement de la phase inaugurale de son service de [...] Read more »
King Faisal Specialist Hospital and Research Centre Announces Innovative Clinical Pharmacogenomics
RIYADH, Saudi Arabia, Oct. 24, 2023 (GLOBE NEWSWIRE) — The King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the launch of the inaugural phase of its clinical pharmacogenomics [...] Read more »
Datacubed Health Launches eClinical Platform App in China, Ensuring Full Compliance and Accessibility
New York, New York, Sept. 26, 2023 (GLOBE NEWSWIRE) — Read more »
Purdue researcher awarded $1.3 million for malaria drug trials in Southeast Asia and Africa
WEST LAFAYETTE, Ind., Sept. 15, 2023 (GLOBE NEWSWIRE) — A Purdue researcher is taking a giant leap forward in the fight against drug–resistant strains of malaria in developing countries.
A Curia apoia o ensaio clínico de fase 1 da nova vacina de RNA de última geração da Replicate Bioscience
ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — A Curia, uma organizao lder em pesquisa, desenvolvimento e fabricao por contrato, anunciou hoje que sua parceira, Replicate Bioscience, recebeu autorizao IND da FDA e dosou o primeiro [...] Read more »
Curia unterstützt die klinische Studie der Phase 1 von Replicate Bioscience mit einem neuartigen RNA-Impfstoff der nächsten Generation
ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, ein fhrendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen, gab heute bekannt, dass sein Partner Replicate Bioscience die IND–Freigabe von der [...] Read more »
Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine
ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced that its partner, Replicate Bioscience, has received IND clearance from the [...] Read more »
Curia soutient l'essai clinique de phase 1 de Replicate Bioscience sur un vaccin novateur à base d'ARN de nouvelle génération
ALBANY, ÉTAT DE NEW YORK, 13 sept. 2023 (GLOBE NEWSWIRE) — Curia, une organisation de recherche, dveloppement et fabrication en sous–traitance de premier plan, a annonc aujourd'hui que son partenaire, Replicate [...] Read more »
Lifezone Metals Reports Completion of Tembo Zone Infill Drilling at the Kabanga Nickel Project with 41 m Intersect at 2.07% Ni, including 16.4 m at 2.77% Ni
New York (United States), Dar es Salaam (Tanzania), Aug. 31, 2023 (GLOBE NEWSWIRE) — Lifezone Metals Limited ("Lifezone Metals" or the "Company") (NYSE: LZM), a modern metals company creating value [...] Read more »
Zenas BioPharma Publica Fase 2 do Estudo Clínico do Obexelimabe, um Tratamento Investigativo da Doença Relacionada à IgG4 (IgG4-RD), no The Lancet Rheumatology
Estudo revelou que o obexelimabe produziu melhora clnica rpida, forte e sustentada, incluindo remisso clnica completa, na maioria dos pacientes com IgG4–RD ativa
Os resultados apoiam o [...] Read more »
Zenas BioPharma gibt die Veröffentlichung von Daten zu einer Phase-2-Studie mit Obexelimab, einem Prüfpräparat zur Behandlung der IgG4-assoziierten Erkrankung (IgG4-RD), im Fachjournal „The Lancet Rheumatology“ bekannt
Die Studie ergab, dass Obexelimab bei den meisten Patientinnen und Patienten mit aktiver IgG4–RD zu einer schnellen, deutlichen und anhaltenden klinischen Verbesserung, einschlielich einer vollstndigen klinischen [...] Read more »